On August 30th 2016, Regenics AS signed a Letter of Intent and a MTA (Material Transfer Agreement) with the 3D Bioprinting Center at Chalmers University of Technology. The 3D Bioprinting Center will explore salmon roe extract as an ingredient in bioink for 3D printing of artificial skin. The working hypothesis is that salmon roe extract may be able to boost colllagen production in embedded fibroblasts, thus creating the first collagen producing artificial skin. The project will also explore the effect of the salmon roe extract in artificial tumors made from basalioma cells.

The 3D Bioprinting Center at Chalmers University of Technology is open to research groups from hospitals, industry and academy with an interest in tissue engineering and 3D  cell culture. The center has state of the art equipment  for  printing  cells  and tissues needed for research, drug screening and tissue engineering; and for evaluation of tailor made biocompatible biomaterials, or bioinks, for 3D bioprinting with living cells. The center was  established  in  January  2015 and has several ongoing projects including cartilage, skin and adipose tissue  engineering.



Two 3D bioprinters available at the center; a 3D Discovery from regenHu, Switzerland, and an INKREDIBLE+ from Swedish start-up Cellink. In addition, the 3D Bioprinting Center offers rheology measurements of bioinks, medical 3D modelling, conventional 3D printing and cell culture facilities. 


At the center, researcher are welcome to print living cells, as well as culture cells before and after printing. The center can assist with study design and technical expertise. The center is also open for researchers wanting to test their materials for 3D bioprinting, and they can assist in tailor-made bioink development and modification for specific purposes. A cell compatible bioink, Cellink, has been developed in house and is now commercially available.


 Contact information:


Chalmers University of Technology
SE-412 96 Gothenburg

Website: www.chalmers.se

Regenics' contact person:
Professor Paul Gatenholm
e-mail: paul.gatenholm@chalmers.se 

Doctor Daniel Hägg
e-mail: daniel.hagg@chalmers.se

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.